Highlights:
-Lower thrombosis risk with newer generation drug-eluting stents
-Intra-aortic balloon counterpulsation does not appear to provide benefit
-“Prasugrel or ticagrelor should be administered to patients at clinical high risk for stent thrombosis”
-Profile: Ulrich Sigwart
[pdfviewer width=”100%” height=”940px” beta=”true”]http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/06/Cardiovascular-News-23.pdf[/pdfviewer]
